Emerging Players in Prostate Cancer-Bone Niche Communication.
Antineoplastic Agents
/ pharmacology
Bone Neoplasms
/ drug therapy
Cell Communication
/ drug effects
Cell Differentiation
/ drug effects
Cell Line, Tumor
Coculture Techniques
Extracellular Vesicles
/ drug effects
Humans
Male
Neoplasm Staging
Osteoblasts
/ drug effects
Osteogenesis
/ drug effects
Prostate
/ pathology
Prostatic Neoplasms
/ diagnosis
bone metastasis
cancer-associated osteoblasts
osteomimicry
prostate cancer
tumor-derived extracellular vesicles
tumor-educated osteoblasts
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
29
07
2020
revised:
21
09
2020
accepted:
28
09
2020
pubmed:
5
12
2020
medline:
1
10
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts have been proposed as major contributors of osteotropism by PCa. Here, we highlight the emerging role of PCa-derived extracellular vesicles (EVs) in reprogramming osteoblasts and support of premetastatic niche formation. We also develop the concept of cancer-associated osteoblasts (CAOs) and outline the potential of PCa cells to acquire an osteoblastic phenotype, termed osteomimicry, as two strategies that PCa utilizes to create a favorable protected niche. Finally, we delineate future research that may help to deconstruct the complexity of PCa osteotropism.
Identifiants
pubmed: 33274720
pii: S2405-8033(20)30262-4
doi: 10.1016/j.trecan.2020.09.006
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112-121Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.